Catalog No.: PC-20873Not For Human Use, Lab Use Only.
Etoricoxib (MK-0663) is a potent, selective and orally active inhibitor of COX-2 with IC50 of 1.1 uM for COX-2 (LPS-induced prostaglandin E2 synthesis), shows no activity against COX-1.
Etoricoxib (MK-0663) is a potent, selective and orally active inhibitor of COX-2 with IC50 of 1.1 uM for COX-2 (LPS-induced prostaglandin E2 synthesis), shows no activity against COX-1. Etoricoxib does not inhibit platelet or human recombinant COX-1 under most assay conditions (IC50>100 uM). Etoricoxib is a potent inhibitor in models of carrageenan-induced paw edema (ID(50) 0.64 mg/kg), carrageenan-induced paw hyperalgesia (ID(50)=0.34 mg/kg), LPS-induced pyresis (ID(50) = 0.88 mg/kg), and adjuvant-induced arthritis (ID(50)=0.6 mg/kg/day) in rats. Etoricoxib reversed LPS-induced pyresis by 81% within 2 h of administration at a dose of 3 mg/kg and showed no effect in a fecal 51Cr excretion model of gastropathy at 100 mg/kg/day for 5 days.
